<?xml version="1.0" encoding="utf-8"?>
<rss 
  version="2.0">
  <channel xmlns:dc="http://dublincore.org/documents/dcmi-namespace/" xmlns:media="http://search.yahoo.com/mrss/">
    <title>Eastgate Biotech</title>
    <link>https://www.globenewswire.com/rssfeed/organization/Gqs6K1D4ICVaj7orinkDuQ==</link>
    <description>Contains the last 20 releases</description>
    <copyright>Copyright 2017, Eastgate Biotech</copyright>
    <managingEditor>newsdesk@globenewswire.com (NewsDesk)</managingEditor>
    <lastBuildDate>Tue, 30 May 2017 13:15:00 GMT</lastBuildDate>
    <webMaster>webmaster@globenewswire.com (Webmaster)</webMaster>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2017/05/30/1023579/0/en/EastGate-Biotech-s-Recent-Acquisition-OMNI-Surgery-Anti-Aging-Centre-Presents-the-OMNI-School-of-Medical-Esthetics.html</guid>
      <link>https://www.globenewswire.com/news-release/2017/05/30/1023579/0/en/EastGate-Biotech-s-Recent-Acquisition-OMNI-Surgery-Anti-Aging-Centre-Presents-the-OMNI-School-of-Medical-Esthetics.html</link>
      <title>EastGate Biotech's Recent Acquisition, OMNI Surgery + Anti-Aging Centre, Presents the OMNI School of Medical Esthetics </title>
      <description><![CDATA[<p>WEST CALDWELL, NJ and TORONTO, ON--(Marketwired - May 30, 2017) -  EastGate Biotech Corp. (<exchange name="OTC PINK">OTC PINK</exchange>: <ticker name="ETBI">ETBI</ticker>), an emerging pharmaceutical company that focuses on innovative pharmaceutical developments and produces and distributes innovative and healthy nutraceuticals based on natural therapies has announced that its recent acquisition,&#160;OMNI Surgery and Anti-Aging Centre is introducing the OMNI School of Medical Esthetics.</p>]]></description>
      <pubDate>Tue, 30 May 2017 13:15 GMT</pubDate>
      <dc:identifier>1023579</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>EastGate Biotech Corp.</dc:contributor>
      <dc:modified>Tue, 19 Sep 2017 02:23 GMT</dc:modified>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2017/04/12/1023577/0/en/EastGate-Biotech-s-Recent-Acquisition-OMNI-Surgery-Anti-Aging-Centre-Appoints-Dr-Ishaan-Sundar-as-Medical-Director.html</guid>
      <link>https://www.globenewswire.com/news-release/2017/04/12/1023577/0/en/EastGate-Biotech-s-Recent-Acquisition-OMNI-Surgery-Anti-Aging-Centre-Appoints-Dr-Ishaan-Sundar-as-Medical-Director.html</link>
      <title>EastGate Biotech's Recent Acquisition OMNI Surgery + Anti-Aging Centre Appoints Dr. Ishaan Sundar as Medical Director </title>
      <description><![CDATA[<p>WEST CALDWELL, NJ and TORONTO, ON--(Marketwired - Apr 12, 2017) -  EastGate Biotech Corp. (<exchange name="OTC PINK">OTC PINK</exchange>: <ticker name="ETBI">ETBI</ticker>) (<a rel="nofollow" href="http://finance.yahoo.com/quote/ETBI?p=ETBI" title="">http://finance.yahoo.com/quote/ETBI?p=ETBI</a>), an emerging pharmaceutical company that produces and distributes innovative and healthy nutraceuticals based on natural therapies as well as focusing on new pharmaceutical developments has announced that its recent acquisition, OMNI Surgery and Anti-Aging Centre has appointed a new Medical Director.&#160;Dr. Ishaan Sundar has assumed the role of Medical Director effective immediately. Educated by the American Academy of Aesthetic Medicine, American Cosmetic Cellular Medicine Association, Laser Sheer Training Academy and trained in Injectable Placements, Dr. Sundar brings over 20 years of extensive practice to the OMNI state-of-the-art centre.&#160;With a distinguished career in Critical Care Medicine (ICU, CCU), Dr. Sundar will oversee medical and surgical operations at Saskatchewan's only combined fee-for-service surgical and anti-aging centre.</p>]]></description>
      <pubDate>Wed, 12 Apr 2017 13:00 GMT</pubDate>
      <dc:identifier>1023577</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>EastGate Biotech Corporation</dc:contributor>
      <dc:modified>Tue, 19 Sep 2017 02:23 GMT</dc:modified>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2017/04/04/1023573/0/en/Pharmaceutical-Biotech-Research-Company-EastGate-Biotech-Corporation-and-AC-Nova-Technologies-ATI-Pharma-Announce-a-Joint-Venture-to-Commercialize-Evidence-Based-Natural-Therapies-.html</guid>
      <link>https://www.globenewswire.com/news-release/2017/04/04/1023573/0/en/Pharmaceutical-Biotech-Research-Company-EastGate-Biotech-Corporation-and-AC-Nova-Technologies-ATI-Pharma-Announce-a-Joint-Venture-to-Commercialize-Evidence-Based-Natural-Therapies-.html</link>
      <title>Pharmaceutical Biotech Research Company EastGate Biotech Corporation and AC Nova Technologies (ATI Pharma) Announce a Joint Venture to Commercialize Evidence-Based Natural Therapies Focused on Glucose Balance and Cardiovascular Health </title>
      <description><![CDATA[<p>WEST CALDWELL, NJ and TORONTO, ON--(Marketwired - Apr 4, 2017) -  EastGate Biotech Corp. (<exchange name="OTC PINK">OTC PINK</exchange>: <ticker name="ETBI">ETBI</ticker>), an emerging pharmaceutical and biotech research company that develops, produces and distributes innovative and healthy nutraceuticals, has announced that it has entered into a Joint Venture with AC Nova Technologies Inc. (ATI Pharma).&#160;The synergy of talents and products means that these two start-up emerging pharmaceutical companies will now provide expertise starting with formulation development to clinical research and product launch.&#160;Both EastGate Biotech (<a rel="nofollow" href="http://www.eastgatebiotech.com/" title="www.EastGateBiotech.com">www.EastGateBiotech.com</a>) and ATI Pharma (<a rel="nofollow" href="http://www.atipharma.com/" title="www.atipharma.com">www.atipharma.com</a>) are focused on products that although naturally occurring are selected based on extensive evidence-based research in both animals and humans.&#160;The focus of their therapies is to slow down the onset of aging by maintaining cellular health of key systems.</p>]]></description>
      <pubDate>Tue, 04 Apr 2017 12:30 GMT</pubDate>
      <dc:identifier>1023573</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>EastGate Biotech Corp.</dc:contributor>
      <dc:modified>Tue, 19 Sep 2017 02:23 GMT</dc:modified>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2017/03/14/1023570/0/en/EastGate-Biotech-Acquires-a-Private-Surgery-Centre-Omni-Surgery-Anti-Aging-Centre.html</guid>
      <link>https://www.globenewswire.com/news-release/2017/03/14/1023570/0/en/EastGate-Biotech-Acquires-a-Private-Surgery-Centre-Omni-Surgery-Anti-Aging-Centre.html</link>
      <title>EastGate Biotech Acquires a Private Surgery Centre, Omni Surgery + Anti-Aging Centre </title>
      <description><![CDATA[<p><em><p>Purchase terms include implementation of Franchise Plan across all markets</p></em></p><p>WEST CALDWELL, NJ and TORONTO, ON--(Marketwired - Mar 14, 2017) -  EastGate Biotech Corp. (<exchange name="OTC PINK">OTC PINK</exchange>: <ticker name="ETBI">ETBI</ticker>), an emerging pharmaceutical company that produces and distributes innovative and healthy nutraceuticals based on natural therapies has announced that it has entered into a Purchase and Sale Agreement to acquire OMNI Surgery and Anti-Aging Centre. This investment will complement EastGate's product development initiatives, potential clinical development, bolster revenues positively and increase the company's asset base. The private fully-accredited multi-specialty facility will serve as a vehicle for merger and acquisition activities of new product lines and medical groups and other existing health care clinics to optimize surgical procedures to improve treatment outcomes for patients.</p>]]></description>
      <pubDate>Tue, 14 Mar 2017 13:30 GMT</pubDate>
      <dc:identifier>1023570</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>EastGate Biotech Corp.</dc:contributor>
      <dc:modified>Tue, 19 Sep 2017 02:23 GMT</dc:modified>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2016/02/08/1023567/0/en/Eastgate-Biotech-CEO-Anna-Gluskin-Talks-to-TheStockRadio-com-About-Eastgate-s-Products-and-Delivery-Technology.html</guid>
      <link>https://www.globenewswire.com/news-release/2016/02/08/1023567/0/en/Eastgate-Biotech-CEO-Anna-Gluskin-Talks-to-TheStockRadio-com-About-Eastgate-s-Products-and-Delivery-Technology.html</link>
      <title>Eastgate Biotech CEO Anna Gluskin Talks to 'TheStockRadio.com' About Eastgate's Products and Delivery Technology </title>
      <description><![CDATA[<p>WEST CALDWELL, NJ and TORONTO, ON--(Marketwired - Feb 8, 2016) -  EastGate Biotech Corp. (<exchange name="OTC PINK">OTC PINK</exchange>: <ticker name="ETBI">ETBI</ticker>), an emerging pharmaceutical company aimed at utilizing drug delivery innovations in the development of improved novel formulations and alternative dosage forms of existing biologically active molecules, announces that its CEO, Anna Gluskin, was interviewed on TheStockRadio.com about their products and delivery technology.</p>]]></description>
      <pubDate>Mon, 08 Feb 2016 13:30 GMT</pubDate>
      <dc:identifier>1023567</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>EastGate Biotech Corp.</dc:contributor>
      <dc:modified>Tue, 19 Sep 2017 02:23 GMT</dc:modified>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2016/01/19/1023564/0/en/EastGate-Biotech-Receives-Notice-of-Publication-From-the-US-Patent-and-Trademark-Office-for-Two-Patents-for-the-Company-s-Proprietary-Intraoral-Lorazepam-Spray.html</guid>
      <link>https://www.globenewswire.com/news-release/2016/01/19/1023564/0/en/EastGate-Biotech-Receives-Notice-of-Publication-From-the-US-Patent-and-Trademark-Office-for-Two-Patents-for-the-Company-s-Proprietary-Intraoral-Lorazepam-Spray.html</link>
      <title>EastGate Biotech Receives Notice of Publication From the US Patent and Trademark Office for Two Patents for the Company's Proprietary Intraoral Lorazepam Spray </title>
      <description><![CDATA[<p>WEST CALDWELL, NJ and TORONTO, ON--(Marketwired - Jan 19, 2016) -  EastGate Biotech Corp. (<exchange name="OTC PINK">OTC PINK</exchange>: <ticker name="ETBI">ETBI</ticker>), an emerging pharmaceutical company aimed at utilizing drug delivery innovations in the development of improved novel formulations and alternative dosage forms of existing biologically active molecules has received the notice of publication from the US Patent and Trademark Office for two patents for the company's intraoral Lorazepam Spray.</p>]]></description>
      <pubDate>Tue, 19 Jan 2016 14:30 GMT</pubDate>
      <dc:identifier>1023564</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>EastGate Biotech Corp.</dc:contributor>
      <dc:modified>Tue, 19 Sep 2017 02:23 GMT</dc:modified>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2016/01/06/1023562/0/en/Eastgate-Biotech-Receives-Repeat-Purchase-Order-From-Its-Canadian-Distributor.html</guid>
      <link>https://www.globenewswire.com/news-release/2016/01/06/1023562/0/en/Eastgate-Biotech-Receives-Repeat-Purchase-Order-From-Its-Canadian-Distributor.html</link>
      <title>Eastgate Biotech Receives Repeat Purchase Order From Its Canadian Distributor </title>
      <description><![CDATA[<p>SALT LAKE CITY, UT and TORONTO, ON--(Marketwired - Jan 6, 2016) -  EastGate Biotech Corp. (<exchange name="OTC PINK">OTC PINK</exchange>: <ticker name="ETBI">ETBI</ticker>), an emerging pharmaceutical company aimed at utilizing drug delivery innovations in the development of improved novel formulations and alternative dosage forms of existing biologically active molecules has received a repeat purchase order from its Canadian distributor Preferred Nutrition (<a rel="nofollow" href="http://www.pno.ca/" title="www.pno.ca">www.pno.ca</a>). As per the agreed upon sales terms the company has received a cash deposit for this order.</p>]]></description>
      <pubDate>Wed, 06 Jan 2016 14:30 GMT</pubDate>
      <dc:identifier>1023562</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>EastGate Biotech Corp.</dc:contributor>
      <dc:modified>Tue, 19 Sep 2017 02:23 GMT</dc:modified>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2015/09/29/1023560/0/en/EastGate-Biotech-Announces-the-Commencement-of-Scale-Up-Manufacturing-Activities-for-Its-Proprietary-Intraoral-Insulin-Tablet.html</guid>
      <link>https://www.globenewswire.com/news-release/2015/09/29/1023560/0/en/EastGate-Biotech-Announces-the-Commencement-of-Scale-Up-Manufacturing-Activities-for-Its-Proprietary-Intraoral-Insulin-Tablet.html</link>
      <title>EastGate Biotech Announces the Commencement of Scale-Up Manufacturing Activities for Its Proprietary Intraoral Insulin Tablet </title>
      <description><![CDATA[<p>SALT LAKE CITY, UT and TORONTO, ON--(Marketwired - Sep 29, 2015) -  EastGate Biotech Corp. (<exchange name="OTC PINK">OTC PINK</exchange>: <ticker name="ETBI">ETBI</ticker>), an emerging pharmaceutical company aimed at utilizing drug delivery innovations in the development of improved novel formulations and alternative dosage forms of existing biologically active molecules, has announced that it has commenced scale-up activities for its proprietary intraoral insulin tablet. </p>]]></description>
      <pubDate>Tue, 29 Sep 2015 13:30 GMT</pubDate>
      <dc:identifier>1023560</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>EastGate Biotech Corp.</dc:contributor>
      <dc:modified>Tue, 19 Sep 2017 02:23 GMT</dc:modified>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2015/09/24/1023558/0/en/EastGate-Biotech-Creates-an-Online-Directory-as-a-Marketing-Tool-for-Its-Nutraceutical-Product.html</guid>
      <link>https://www.globenewswire.com/news-release/2015/09/24/1023558/0/en/EastGate-Biotech-Creates-an-Online-Directory-as-a-Marketing-Tool-for-Its-Nutraceutical-Product.html</link>
      <title>EastGate Biotech Creates an Online Directory as a Marketing Tool for Its Nutraceutical Product </title>
      <description><![CDATA[<p>SALT LAKE CITY, UT and TORONTO, ON--(Marketwired - Sep 24, 2015) -  EastGate Biotech Corp. (<exchange name="OTC PINK">OTC PINK</exchange>: <ticker name="ETBI">ETBI</ticker>), an emerging pharmaceutical company aimed at utilizing drug delivery innovations in the development of improved novel formulations and alternative dosage forms of existing biologically active molecules created an online directory for stores carrying E-drops, marketed as UTI drops by our Canadian distributor, Preferred Nutrition Inc. (<a rel="nofollow" href="http://www.pno.ca" title="www.pno.ca">www.pno.ca</a>).</p>]]></description>
      <pubDate>Thu, 24 Sep 2015 13:30 GMT</pubDate>
      <dc:identifier>1023558</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>EastGate Biotech Corp.</dc:contributor>
      <dc:modified>Tue, 19 Sep 2017 02:23 GMT</dc:modified>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2015/07/07/1023556/0/en/EastGate-Biotech-Announces-That-Its-Research-Collaborator-the-University-of-Guelph-Department-of-Molecular-and-Cellular-Biology-Receives-NSERC-Grant.html</guid>
      <link>https://www.globenewswire.com/news-release/2015/07/07/1023556/0/en/EastGate-Biotech-Announces-That-Its-Research-Collaborator-the-University-of-Guelph-Department-of-Molecular-and-Cellular-Biology-Receives-NSERC-Grant.html</link>
      <title>EastGate Biotech Announces That Its Research Collaborator, the University of Guelph, Department of Molecular and Cellular Biology Receives NSERC Grant </title>
      <description><![CDATA[<p>SALT LAKE CITY, UT and TORONTO, ON--(Marketwired - Jul 7, 2015) -  EastGate Biotech Corp. (<exchange name="OTC PINK">OTC PINK</exchange>: <ticker name="ETBI">ETBI</ticker>), an emerging pharmaceutical company aimed at utilizing drug delivery innovations in the development of improved novel formulations and alternative dosage forms of existing biologically active molecules, has announced that its research collaborator, the University of Guelph, Department of Molecular and Cellular Biology received a grant from the National Sciences and Engineering Research Council of Canada (NSERC).&#160;The grant was approved for the development and evaluation of new nano delivery vehicles for natural antimicrobial products with improved efficacy..</p>]]></description>
      <pubDate>Tue, 07 Jul 2015 13:30 GMT</pubDate>
      <dc:identifier>1023556</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>EastGate Biotech Corp.</dc:contributor>
      <dc:modified>Tue, 19 Sep 2017 02:23 GMT</dc:modified>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2015/06/09/1023554/0/en/EastGate-Biotech-Announces-That-Impex-Healthcare-Will-Distribute-One-of-Its-Products-Glucora.html</guid>
      <link>https://www.globenewswire.com/news-release/2015/06/09/1023554/0/en/EastGate-Biotech-Announces-That-Impex-Healthcare-Will-Distribute-One-of-Its-Products-Glucora.html</link>
      <title>EastGate Biotech Announces That Impex Healthcare Will Distribute One of Its Products, Glucora </title>
      <description><![CDATA[<p>SALT LAKE CITY, UT and TORONTO, ON--(Marketwired - Jun 9, 2015) - &#160;EastGate Biotech Corp. (<exchange name="OTC PINK">OTC PINK</exchange>: <ticker name="ETBI">ETBI</ticker>), an emerging pharmaceutical company aimed at utilizing drug delivery innovations in the development of improved novel formulations and alternative dosage forms of existing biologically active molecules, has announced that Impex Healthcare (<a rel="nofollow" href="http://www.impexhealthcare.com/" title="www.ImpexHealthcare.com">www.ImpexHealthcare.com</a>) will commence the distribution and marketing of one of the company's natural products, Glucora, in Bangladesh along with future distribution of other glucose management products. </p>]]></description>
      <pubDate>Tue, 09 Jun 2015 13:30 GMT</pubDate>
      <dc:identifier>1023554</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>EastGate Biotech Corp. </dc:contributor>
      <dc:modified>Tue, 19 Sep 2017 02:23 GMT</dc:modified>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2015/05/28/1023553/0/en/EastGate-Biotech-Announces-Collaboration-With-the-University-of-Guelph-Department-of-Molecular-and-Cellular-Biology-for-Its-Natural-Antibacterial-Products.html</guid>
      <link>https://www.globenewswire.com/news-release/2015/05/28/1023553/0/en/EastGate-Biotech-Announces-Collaboration-With-the-University-of-Guelph-Department-of-Molecular-and-Cellular-Biology-for-Its-Natural-Antibacterial-Products.html</link>
      <title>EastGate Biotech Announces Collaboration With the University of Guelph, Department of Molecular and Cellular Biology, for Its Natural Antibacterial Products </title>
      <description><![CDATA[<p>SALT LAKE CITY, UT and TORONTO, ON--(Marketwired - May 28, 2015) - EastGate Biotech Corp. (<exchange name="OTC PINK">OTC PINK</exchange>: <ticker name="ETBI">ETBI</ticker>), an emerging pharmaceutical company aimed at utilizing drug delivery innovations in the development of improved novel formulations and alternative dosage forms of existing biologically active molecules, has announced today its collaboration with the University of Guelph, Department of Molecular and Cellular Biology.&#160;The collaboration involves evaluation of the antimicrobial activity of the company's natural antibacterial products, Cleanezze&#8482; and VClean&#8482;.</p>]]></description>
      <pubDate>Thu, 28 May 2015 13:30 GMT</pubDate>
      <dc:identifier>1023553</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>EastGate Biotech Corp.</dc:contributor>
      <dc:modified>Tue, 19 Sep 2017 02:23 GMT</dc:modified>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2015/05/26/1023551/0/en/EastGate-Biotech-Announces-That-PharmaCenter-Ltd-Will-Commence-Marketing-the-Company-s-Nutraceutical-Products.html</guid>
      <link>https://www.globenewswire.com/news-release/2015/05/26/1023551/0/en/EastGate-Biotech-Announces-That-PharmaCenter-Ltd-Will-Commence-Marketing-the-Company-s-Nutraceutical-Products.html</link>
      <title>EastGate Biotech Announces That PharmaCenter Ltd. Will Commence Marketing the Company's Nutraceutical Products </title>
      <description><![CDATA[<p>SALT LAKE CITY, UT and TORONTO, ON--(Marketwired - May 26, 2015) -  EastGate Biotech Corp. (<exchange name="OTCBB">OTCBB</exchange>: <ticker name="ETBI">ETBI</ticker>), an emerging pharmaceutical company aimed at utilizing drug delivery innovations in the development of improved novel formulations and alternative dosage forms of existing biologically active molecules, has announced that PharmaCenter (<a rel="nofollow" href="http://www.pharmacenter.sk/" title="www.PharmaCenter.sk">www.PharmaCenter.sk</a> or <a rel="nofollow" href="http://www.pharmacenter.hu/" title="www.PharmaCenter.hu">www.PharmaCenter.hu</a>) will commence marketing E-drops, one of the company's nutraceutical products in Slovakia and Czech Republic.</p>]]></description>
      <pubDate>Tue, 26 May 2015 15:14 GMT</pubDate>
      <dc:identifier>1023551</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>EastGate Biotech Corp. </dc:contributor>
      <dc:modified>Tue, 19 Sep 2017 02:23 GMT</dc:modified>
    </item>
  </channel>
</rss>